Transforming growth factor-β (TGFβ) is enriched in the bone matrix and serves as a key factor in promoting bone metastasis in cancer. In addition, TGFβ signaling activates mammalian target of rapamycin (mTOR) functions, which is important for the malignant progression. Here, we demonstrate that TGFβ regulates the level of microRNA-96 (miR-96) through Smad-dependent transcription and that miR-96 promotes the bone metastasis in prostate cancer. The enhanced effects in cellular growth and invasiveness suggest that miR-96 functions as an oncomir/and metastamir. Supporting this idea, we identified a downstream target of the TGFβ-miR-96 signaling pathway to be AKT1S1 mRNA, whose translated protein is a negative regulator of mTOR kinase. Our findings provide a novel mechanism accounting for the TGFβ signaling and bone metastasis.
INTRODUCTION
Transforming growth factor-β (TGFβ) signaling exhibits complicated features in cancer biology in that TGFβ is considered as tumor promoter 1 and suppressor. [1] [2] [3] In prostate and other types of cancer, a general pattern is that TGFβ signaling suppresses tumor growth in normal/benign tissues while enhancing malignancy (for example, invasion and metastases) in tumorigenic tumor cells. [4] [5] [6] Current hypothesis to explain this apparent paradox is that the effector pathways and their associated factors in response to TGFβ signaling are dependent on individual cellular-context. [4] [5] [6] TGFβ signaling is intrinsically complex for the diverse environments in tumor cells. In the case of Smad-dependent canonical signaling, there are combinatory interactions of type I and type II receptors and receptor-activated Smads along with their corresponding transcription complexes. 7 In addition, following Smadindependent noncanonical signaling, TGFβ receptors directly activate many receptor pathways that response to factors other than TGFβ superfamily. 7 Among many Smad-independent pathways, the PI3K-AKT-mTOR axis is important for the malignant progression 4, 8, 9 and pathological bone metastases. 10 The mammalian mTOR exists in two distinct complexes called mTORC1 and mTORC2. 11 Activation of mTOR in response to growth factors results in the phosphorylation of numerous substrates, including the phosphorylation of S6 kinase by mTORC1 and AKT by mTORC2. 11 A positive regulation toward mTORC1 by mTORC2 is established, as one of the key regulators for mTORC1 kinase is identified to be an AKT substrate, AKT1S1 (also known as PRAS40). 12, 13 Phosphorylation of AKT1S1 by AKT results in the activation of mTOR kinase due to the dissociation of the AKT1S1-mTORC1 complex followed by disruption of the inhibitory effect of AKT1S1. 12, 13 As mTOR activity is tightly associated with many aspects of tumorigenesis, 14 the inhibitory role of AKT1S1 has raised a great interest of its regulation by mechanisms other than AKT phosphorylation. Emerging evidence has shown that microRNAs (miRs) have important roles in metastases 15 and regulate many components in the TGFβ signaling pathway. 16 It is possible that, following TGFβ signaling, miRs modulate mTOR functions to commit the malignant progression.
In the current study, we have identified microRNA-96 (miR-96) as a key factor in metastatic prostate cancer in response to TGFβ signaling. We demonstrated that the Smad-dependent canonical pathway is the key mechanism responsible for the induction of miR-96 transcription. We showed that miR-96 targets at the 3′untranslated regions (3′UTRs) of AKT1S1 mRNA and leads to its downregulation affecting the protein level. As expected, the phosphorylation levels of S6K, a key mTOR kinase substrate, are positively regulated by miR-96 and inversely correlated with the levels of AKT1S1. In addition, the inhibitory effects of TGFβ-miR-96 signaling on AKT1S1 expression were confirmed in tissue samples from prostate cancer patients showing an inverse correlation between miR-96 and AKT1S1 levels. Finally, based on results derived from multiple approaches including cell line proliferation/invasion assays, clinical database analyses and mouse bone metastasis model, we concluded that miR-96 can promote bone metastasis and contribute to reduced survival rates. This study supports that miR-96 could be served as a prognostic marker and a potential target of therapeutics for metastatic prostate cancers.
RESULTS
The level of miR-96 is regulated by the TGFβ-Smad signaling We have established several clonal cell lines (AC1, AC3 and SC1) derived from the prostate-specific, Pten/TP53 double knockout mice 17 to study the roles of microRNAs (miRs) following TGFβ signaling. 18 Using this system, some miRs (for example, miR-1) have been characterized with tumor-suppressive functions and with downregulation pattern following TGFβ treatment. 18 Compared with the cell line derived from late-stage sarcomatoid carcinoma (SC1), only cell lines derived from adenocarcinoma (AC1 and AC3) showed constitutive TGFβ signaling as evidenced by elevated phosphorylation levels of Smad2 (Figure 1a ).
Interestingly, we have reported that only AC3 is capable of undergoing epithelial-mesenchymal transition (EMT) following TGFβ treatment as confirmed again by the induction of vimentin (Vim, Figure 1b ), consistent with our earlier studies. 17 The lack of EMT response in SC1 could be due to its late/or terminal stage that contains much lower Smad2 levels and shuts off TGFβ signaling ( Figure 1a ).
Using this mouse prostate cancer system, we identified that miR-96 was upregulated by TGFβ in a time-dependent manner in cell lines derived from adenocarcinoma but not from sarcomatoid carcinoma (AC1 and AC3 versus SC1, Figure 1c ). The upregulation feature of miR-96 is distinct from our previously characterized miR-96 regulates mTOR signaling in prostate cancer miRs (for example, miR-1 and miR-200), which showed downregulaton pattern. 18 In addition, the irresponsiveness to TGFβinduced EMT in both AC1 and SC1 did not warrant a consistent outcome in predicting miR-96 response, as we observed induction of miR-96 in a time-dependent manner in AC1 but not SC1 ( Figure 1c ). Interestingly, when cells were treated with TGFβ type I receptor inhibitor, the steady-state levels of endogenous miR-96 were reduced (SB431542, Figure 1d ), suggesting a background activation of TGFβ signaling possibly due to serum-derived TGFβ. Besides, this result supports the idea that the regulation of miR-96 is tightly associated with the activity of TGFβ signaling. To further confirm the association between miR-96 and TGFβ signaling, we examined the gene expression profiles in a public prostate cancer data base maintained at Memorial Sloan-Kettering Cancer Center. 19 After analyzing the database (containing 98 primary tumor and 13 distant metastasis samples) by gene set enrichment analysis, we observed that miR-96 is correlated with TGFβ gene sets ( Supplementary Figures S1A and B ). In summary, our results substantiate the idea that the miR-96 expression is a downstream event of the TGFβ signaling pathway.
Smad-dependent transcription induces miR-96 following TGFβ signaling To investigate how TGFβ signaling transcriptionally regulates miR-96 expression, we looked closely at the putative promoter region upstream of the mouse primary miR (pri-miR) transcripts encoding miR-96, located in the mouse chromosome 6. Following sequence analysis, we identified two Smad2/3-binding elements (SBEs) within the promoter region ( Figure 1e ). To further test whether Smad2/3 directly mediates the TGFβ-dependent pri-miR-96 transcription, we performed chromatin immunoprecipitation (ChIP) assay in AC1 and AC3 cell lines following quantitative PCR analyses. As shown in Figure 1f , significant increase in Smad2/3 and Smad4 signals only occurred at both SBEs after TGFβ treatment. In addition, we performed promoter assay to examine whether the individual SBE in the promoter region is functional. Using fluorescent protein (RFP) as reporter, we demonstrated that TGFβ indeed increases the RFP levels by monitoring its median fluorescent intensity using either SBE1 or SBE2 (left panel, Figure 1g ). Furthermore, we characterized the specificity of Smads binding in the promoter region of pri-miR-96 by introducing point mutation ( Figure 1e ). We found that only mutation at SBE2 disrupts the ability of TGFβ to induce RFP expression in the promoter assay (right panel, Figure 1g ). These data suggest a molecular mechanism by which TGFβ regulates pri-miR-96 transcription through a physical interaction between the Smad2/3/4 complex and the promoter region of pri-miR-96.
AKT1S1 is a bona fide target of miR-96 and tightly regulated by TGFβ signaling To address the molecular mechanism of miR-96, we focused on searching its targeting substrates that could be involved in promoting malignancy. Earlier studies have shown that miR-96 suppresses FOXO1 and enhances proliferation. 20 In our mouse prostate cancer system, we also observed that TGFβ and miR-96 behave similarly to downregulate FOXO1 levels ( Supplementary  Figures S1C and D) . Using a bi-cistronic luciferase assay system with firefly luciferase (FL) as internal control, we combined Renilla luciferase (RL) and the mouse 3′UTR of FOXO1 in one transcriptional unit and monitored the luciferase activities. After normalization (RL/FL), we showed that both TGFβ and miR-96 can reduce the activity of RL consistent to the finding that miR-96 targets to the 3′UTR of FOXO1 leading to its downregulation (Supplementary Figure S1E ). Therefore, we validated our cellular system by recapitulating the inhibitory effects of miR-96 on the tumor suppressor FOXO1.
In addition to FOXO1, we found that AKT1S1 as a potential target with two predicted miR-96-binding sites in the 3′UTR region of the mRNA transcript. We next set up a luciferase reporter system to monitor the regulatory roles of TGFβ-Smad-miR-96 signaling on AKT1S1 by measuring the ratio of RL, representing the levels of AKT1S1 3′UTR, and FL, which served as internal control (Figure 2a ). Consistent with our predicted role of miR-96, we found that TGFβ treatment causes downregulation of AKT1S1 levels in AC1 and AC3 cells; on the other hand, inhibition of TGFβ signaling by inhibitor shows the opposite effects (Figure 2b ), further supporting the idea that the endogenous AKT1S1 levels is a downstream event of TGFβ signaling. To directly assess the effects of miR-96 in the same reporter system, we showed that exogenously expressing miR-96 precursor (labeled '96 pre') represses the luciferase activities and that knockdown of miR-96 (labeled 'anti-miR-96') increases the signals (Figure 2c ). When monitoring the endogenous mRNA levels of AKT1S1 under the same experimental setting, we also found the same regulation pattern in both AC1 and AC3 cell lines (Figure 2d ), consistent with the hypothesis that miR-96 reduces the stability of AKT1S1 mRNA. Furthermore, we asked whether the predicted miR-96-binding sites in the 3′UTR of AKT1S1 do provide specificity by monitoring the luciferase activities of the reporter constructs containing individual mutations at miR-96 target sites (+120 and +649, Figure 2a ). As shown in Figure 2e , we demonstrated that mutation at +649-binding site confers resistance to the inhibitory effects of either TGFβ or miR-96, supporting a physical interaction between miR-96 and AKT1S1 3′UTR.
As mTOR signaling is crucial to the malignant progression of prostate cancer [8] [9] [10] and AKT1S1 protein inhibits the mTOR functions, 13 it is possible that miR-96 promotes aggressive prostate phenotypes through downregulation of AKT1S1 and induction of mTOR activities. Indeed, we observed that TGFβ treatment reduces AKT1S1 protein levels and increases the mTOR phosphorylation, whereas suppression of the TGFβ signaling using specific inhibitor (SB431542) exhibits opposite effects (left panel, Figure 2f ). To directly examine whether miR-96 regulates mTOR activation, we found that overexpression of miR-96 precursor increases mTOR phosphorylation and reduces the protein level of AKT1S1 (right panel, Figure 2f ). Similar to the effect of TGFβ receptor inhibitor, anti-miR-96 reduces mTOR phosphorylation but increases the protein level of AKT1S1 (right panel, Figure 2f ). In summary, we identified AKT1S1 mRNA as a novel substrate of miR-96, and the downregulation of AKT1S1 through miR-96 enhances the mTOR activity following TGFβ signaling.
TGFβ-miR-96 signaling downregulates AKT1S1 and enhances mTOR functions The identification of AKT1S1 mRNA as a direct target of miR-96 in mouse prostate cell lines provides important clues to the function of miR-96. As the AKT1S1 protein is a negative regulator of mTOR, 12, 13 this newly identified pathway has important implication in the tumor progression. Therefore, we asked whether the TGFβ-miR-96-AKT1S1 axis is a general pathway in prostate cancer. We performed experiments using human metastatic prostate cancer cell lines to validate the inhibitory effect of TGFβ-miR-96 signaling on AKT1S1 mRNA. As shown in Figure 3a , we found that TGFβ treatment induces miR-96 levels in PC3 and RasB1 21 cell lines. However, under the same conditions, TGFβ treatment markedly suppressed the levels of AKT1S1 mRNA (Figure 3b ). Next, increasing miR-96 levels by transient transfection (96 pre) decreases the endogenous AKT1S1 levels, whereas knockdown of miR-96 can increase the AKT1S1 levels (anti-miR-96, Figure 3c ). We further performed luciferase reporter assay using the 3′UTR of human AKT1S1. We found that the expression patterns of human AKT1S1 3′UTR are the same as those of mice AKT1S1 3′UTR in response to TGFβ signaling (Figure 3d When we monitored the protein levels following TGFβ treatment, the AKT1S1 level is reduced and the mTOR kinase activity is increased as evidenced by the induced phosphorylation of S6 kinase (P-S6K, Figure 3f ). Similar to the effect of TGFβ, overexpression of miR-96 precursor also reduced the AKT1S1 levels and stimulated the mTOR kinase activity showing increased phosphorylation levels of S6 kinase (Figure 3f and Supplementary Figure S1D ). Upon introducing miR-96 precursor, the endogenous protein levels of mTOR and S6K are also increased (96 pre, Figure 3f ) consistent with the increased protein synthesis rate following TGFβ signaling. 8 We also observed basal levels of TGFβ signaling likely because of serum-derived TGFβ as TGFβ receptor inhibitor (SB431542) significantly reduces the levels of miR-96 ( Figure 1d ) and the phosphorylation levels of S6 kinase (Figure 3f ). However, reducing the endogenous miR-96 level by anti-miR-96 overcomes the activation effect of endogenous TGFβ and still reduces the phosphorylation levels of S6 kinase (P-S6K, Figure 3f and Supplementary Figure S1F ). We concluded that Smaddependent transcription of miR-96 has an important role in TGFβ-regulated mTOR functions partly through miR-96-mediated downregulation of AKT1S1.
TGFβ-miR-96 signaling and AKT1S1 level are inversely correlated in human prostate cancer To further confirm the regulatory role of miR-96 and establish the inverse correlation between miR-96 and AKT1S1, we sought to monitor the expression levels directly from the tissue samples of prostate cancer using immunohistochemistry (IHC). First, we analyzed the mRNA levels in 24 independent prostate tumors collected from Wan Fang Hospital, Taipei Medical University, Taiwan. The samples were divided into two groups based on AKT1S1 expression levels, and an analysis of variance showed that the tissues with lower AKT1S1 expression (labeled 'AKT1S1_L') have higher miR-96 levels (Figure 4a ), which is consistent with the downregulation effect of miR-96 observed in prostate cancer cell lines (Figure 2 and Figure 3 ). In addition, an inverse correlation between the miR-96 and AKT1S1 mRNA levels was confirmed by statistical analyses in the clinical samples ( Figure 4b ). We next performed IHC analysis in distant metastatic tumors to directly monitor the AKT1S1 protein levels. Consistent with our finding that induction of miR-96 is TGFβ-Smad-dependent (Figure 1) , we observed strong TGFβ signaling only in prostate cancer samples with higher miR-96 expression levels as evidenced by the nuclear phospho-Smad2 staining (upper panel, Figure 4c ). However, when we monitored the AKT1S1 protein levels in the continuous tissue section, tumor with lower miR-96 levels show intensive AKT1S1 staining compared with the tissue samples with higher miR-96 expression (bottom panel, Figure 4c ). Quantification of the images taken from the tissue samples showed that the levels of phospho-Smad2 and AKT1S1 are inverse-correlated (Figure 4d ). When we performed gene set enrichment analysis using a prostate cancer data set, 19 a set of genes that is downregulated by mTOR inhibitor 22 is enriched in the group of cancer expressing lower levels of miR-96 ( Figure 4e ). These results are consistent with our proposed mechanism that the mTOR function is controlled by the status of miR-96 level partly through the regulation of AKT1S1 mRNA. Induction of miR-96 promotes aggressive phenotypes of prostate cancers Accumulating evidence has shown that miRs have an important role in TGFβ-mediated tumor progression. 15 To demonstrate whether miR-96 promotes malignancy in cancer phenotypes, we first examined the levels of miR-96 in a panel of human prostate cancer cell lines. As shown in Supplementary Figure S1G , we found that the levels of miR-96 in metastatic cell lines (PC3 and RasB1) are (Figure 5a ), whereas overexpression of miR-96 in the nonmetastatic DU145 cell line increases the invasion ability (Figure 5b ). We also found that the miR-96-regulated invasiveness is correlated with the proliferation rate, as miR-96 knockdown reduces the rates in PC3 and RasB1 (Figure 5c ), whereas overexpression of miR-96 increases that in DU145 (Figure 5d ). To confirm that TGFβ promotes malignant phenotypes of prostate cancer through the miR-96-mediated pathway, we performed experiments in cells with miR-96 knockdown and monitored the TGFβ-induced invasiveness and proliferation. As expectedly, TGFβ treatment can further enhance both invasion and proliferation rates; however, reducing the levels of miR-96 significantly suppressed the malignant phenotypes in response to TGFβ (ctrl. versus anti-miR-96, Supplementary Figures S2A and B) .
We further investigated the miR-96 levels in the clinical data, 19 containing 28 normal, 98 primary and 13 metastatic prostatic samples. Compared with normal tissues, the intensity mean expression analyses showed progressive increase in miR-96 expression in primary and in metastatic tumor samples (Figure 5e ), which is consistent with a correlation between miR-96 expression and the stages of clinic tumor (Supplementary Figure S2C) . Patients with higher miR-96 expression also have a poorer survival rate (Figure 5f ).
On the basis of the effects observed in metastatic (that is, PC3 and RasB1) and nonmetastatic (that is, DU145) cell lines, we reasoned that the levels of miR-96 determine the malignancy of prostate cancer. To further test this idea, we evaluated the effects of miR-96 in the nonmetastatic DU145 cell line using a mice metastatic model. Compared with control vector (EV), the originally nonmetastatic DU145 cells became highly metastatic and enriched in the bone marrow after overexpression of miR-96 (96 pre) (Figure 6a ). Compared with mice injected with DU145harboring vector control, those with DU145-expressing miR-96 precursor (96 pre) show that the majority of bone marrows in the femurs were occupied by osteolytic tumor cells ( Figure 6b ) and reduced survival rate (Figure 6c ). Taken together, our aggregated Our results support the idea that miR-96 acts as a metastamir/or oncomir partly through its regulation of mTOR functions. As shown in Figure 6d , we proposed a model that TGFβ utilizes the Smad-dependent canonical pathway to stimulate mTOR functions. AKT1S1 suppresses the functions of mTOR through formation of a stable complex. The transcribed pri-miR-96 was processed to pre-miR-96 and miR-96. The recognition of miR-96 to the 3′UTR of AKT1S1 mRNA results in downregulation of AKT1S1 and disruption of the AKT1S1-mTOR complex. Therefore, TGFβ signaling ensures persistent mTOR function and promotes malignant cancer phenotypes leading to poor prognostic outcomes.
DISCUSSION
It has been shown that PTEN and p53 tumor suppressor genes are commonly mutated in cancer. 23, 24 However, only combined Pten/Trp53 deletion showed aggressive and lethal prostate cancer compared with either the Pten or Trp53 gene alone in mice prostate epithelium. 23, 24 In the current study, we identified expression of miR-96 following TGFβ treatment in cell lines derived from the epithelial prostate adenocarcinoma in the Pten/ Trp53 deletion mice 17 (Figure 1 ). On the basis of several lines of evidence, we concluded that miR-96 promotes aggressive cancer phenotypes ( Figure 6 ), which could be considered as a biomarker for diagnostic or prognostic application. Consistent with this notion, it has been shown that the levels of miR-96 were elevated in breast and prostate cancers 20, 25, 26 and correlated with WHO tumor grades. 20 In addition, we and other investigators have found that miR-96 targets several tumor suppressors including AKT1S1 (Figures 2-4 Figures S1C and D) 20, 25 and FOXO3a. 26 Therefore, miR-96 can be considered as a metastamir/or oncomir in prostate cancer.
), FOXO1 (Supplementary
The biological function of miR-96, similar to TGFβ, also exhibits paradoxical property. Although we and others have shown that miR-96 stands as a metastamir/or oncomir in prostate cancer, miR-96 regulates mTOR signaling in prostate cancer MK Siu et al in pancreatic cancer, miR-96 seems to be involved in tumorsuppressive function by suppressing KRAS. 27 It has been observed that re-activation of TGFβ signaling can contribute to cell survival when the RAS signaling is blocked, for example, using cetuximab or vemurafenib to inhibit the RAS pathway, TGFβ signaling is induced to confer survival and resistance. 28, 29 Therefore, it is possible that TGFβ signaling is normally suppressed in cancer cells with sustained RAS signaling for growth and proliferation. Alternatively, the presence of both RAS and TGFβ signaling pathways may produce too strong a survival signal that triggers oncogene-induced senescence. 29 Early-stage tumor cells may be initiated primarily through RAS signaling, 30 and under that environment, reactivation of TGFβ signaling or exogenously introducing miR-96 could suppress RAS levels and exhibit tumor suppressor functions. 27 On the contrary, late-stage/or metastatic tumor cells may have acquired mutations that overcome the suppressor effects of miR-96.
The statuses of tumor suppressors could be a key factor in determining the direction of the paradoxical functions of miR-96. Experiments showing miR-96 as a tumor suppressor 27 were using several pancreatic cell lines (for example, MIA PaCa-2 and PANC-1) that exhibited wild-type p53 function (for example, p53-depedent cell cycle arrest 31 ). However, the mouse adenocarcinoma cell lines used in our study are p53 null (that is, AC1 and AC3) and the human prostate cancer cell lines (for example, PC3 and DU145) are also p53 mutated with poor p53-dependent damage responses. 32, 33 Using two other prostate cancer cell lines with wild-type p53 (LNCap and 22Rv1), 34 we tried to monitor the regulates mTOR functions leading to bone metastases: TGFβ stimulates mTOR functions through the Smad-dependent canonical pathway to induce pri-miR-96 transcription followed by processing to pre-miR-96 and miR-96. miR-96 downregulates AKT1S1 through targeting its mRNA (dialogue box) and derepresses the inhibitory effects of AKT1S1 on mTOR kinase. miR-96 regulates mTOR signaling in prostate cancer effects of miR-96 on invasiveness but failed to detect the invasion property even in the parental cells. Nonetheless, when we compared with the control cell (EV), overexpression of exogenous miR-96 precursor did not promote migration rate (96 pre, Supplementary Figure S2D ). It is possible that only under p53defected conditions TGFβ-miR-96 signaling exhibits tumor progression functions. However, this interpretation could be further complicated by the functional androgen-receptor signaling in the p53 wild-type cell lines (LNCap and 22Rv1). 34 The androgenreceptor-positive cells may attenuate cellular response to TGFβ through multiple mechanisms in addition to downregulation of the TGFβ receptor. 35 It has been shown that AKT1S1 forms a tight complex with mTOR kinase and negatively regulates its activity. Phosphorylation of AKT1S1 by AKT kinase can dissociate the complex and activate mTOR functions. 12, 13 In addition to the PI3K-AKT pathway, our studies provide another mechanism by which the mTOR kinase activity is regulated by Smad-dependent miR-96 ( Figures 2 and 3 and Supplementary Figure S1F ). As mTOR activation is important in tumor progression, the combinational strategies (phosphorylation and downregulation) to shut off the inhibitory effects of AKT1S1 may lead to either hyperactivation or sustained activation of mTOR kinase. Consequently, the mTOR activity following TGFβ signaling is ensured to facilitate metastatic progression. Further studies are required to determine whether there are differential roles in the two pathways to activate mTOR functions.
MATERIALS AND METHODS

Cell culture
The AC1 and AC3 cell lines were isolated from 4-month-old PbCre4 + ; Pten fl/fl ;TP53 fl/fl ;Luc+ prostate tumors. Cloned cell lines using limiting dilution were established as described. 17 The benign prostate hyperplastic epithelial DHMLE and metastatic RasB1 21 cell lines were provided by Dr Yin (NCI, NIH, Bethesda, MD, USA). AC1, AC3 and DHMLE cell lines were cultured in PrEGM media (Lonza, Walkersville, MD, USA). DU145, PC3, LNCap, 22Rv1 and RasB1 cell lines were cultured in RPMI 1640 media supplemented with 10% fetal calf serum (FCS). Transient transfections were carried out using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA). Dosage of TGFβ and SB431542 was TGFβ (10 ng/ml) and SB431542 (1 μM).
Real-time RT-PCR
Total RNA was isolated using mirVana PARIS RNA isolation system (Ambion, Austin, TX, USA). RT-PCR was performed as described in Supplementary information.
Western blot analysis
Cells were lysed with RIPA buffer containing complete protease inhibitors (Roche, San Francisco, CA, USA) plus the phosphatase inhibitors (Roche), 25 mM β-glycerophosphate, 10 mM sodium fluoride and 1 mM Sodium Vanadate were performed as described. 18 Primary antibodies were incubated overnight at 4°C using the dilutions listed in Supplementary Tables ( Supplementary Table S3 ). mR luciferase assay Cells were transfected with 1 μg of mouse or human AKT1S1 3′UTR reporter and 1 μg of empty vector or plasmid encoding miR-96 precursor. The psiCHECK-2 vectors contain both firefly and Renilla luciferase reporters. Cell extracts were prepared 24 h after TGFβ (10 ng/ml) or SB431542 (1 μM) treatment, and the luciferase and Renilla activities were measured using the Dual Luciferase Reporter Assay System (Promega, Madison, WI, USA) as described in Supplementary information.
Invasion assay
Invasion assays were carried out as described in Supplemental information using 1 × 10 6 cells and RPMI 1640 media supplemented with 10% FCS in both chamber.
In vitro growth assay
In vitro growth curves were performed as described in Supplementary information using a density of 2 × 10 3 cells per well.
IHC staining
The clinical samples used 24 primary prostate tumors were collected from Wan Fang Hospital, Taipei Medical University, Taiwan. Immunohistochemistry was performed using AKT1S1 (Cell Signaling, Denvers, MA, USA) and phospho-Smad2 (Millipore, Billerica, MA, USA) antibodies at 1:100 dilution as described in Supplementary information.
FACS analysis
Promoter functional analysis using FACS and relative median fluorescent intensity value was measured as described in Supplementary information.
ChIP assay
ChIP assays were performed using the EZ magna ChIP A kit (Millipore) with a modified protocol as described in Supplementary information.
Animal studies
Animal work was performed in accordance with a protocol approved by the Taipei Medical University Animal Care and Use Committee. To analyze metastasis, 5-week-old male nude mice (NLAC, Taipei) were injected intracardiacly with 1 × 10 5 tumor cells and histology imaging of bone in the femur of tumor-bearing mice were as described. 36 The level of bone metastasis in mouse was quantified based on the following criteria: (0) no metastasis, (1) bone lesion covers less than ¼ of the bone width, (2) bone lesion involves ¼-½ of bone width, (3) bone lesion across ½-¾ of bone width and (4) bone lesion is more than ¾ of bone width. The derived bone metastasis score for each mouse represents the sum of scores of all bone lesions from four limbs. For survival studies, mice were killed when one of the following situations applied: 10% loss of body weight, paralysis or head tilting. All animal studies were repeated three times.
Clinical outcome and correlation analyses using human data sets
We used mRNA expression data from a public human prostate cancer data set. 19 The study was conducted under Memorial Sloan-Kettering Cancer Center Institutional Review Board approval on 28 normal, 151 primary and 19 metastatic samples as described in Supplementary information. gene set enrichment analysis was performed using the software from the Broad Institute. 37 
Statistical analysis
In vivo animal results and clinical outcome analyses are expressed as plots showing the median and box boundaries extending between 25th and 75th percentiles, with whiskers down to the minimum and up to the maximum value. All in vitro data were presented as means ± s.e.m. Statistical calculations were performed with GraphPad Prism (GraphPad Software Inc., La Jolla, CA, USA) analysis tools. Differences between individual groups were analyzed by one-way or two-way analysis of variance test. Bonferroni's post test was used for comparisons among three or more groups. Log-rank test was used for survival curve analysis. P-values less than 0.05 were considered statistically significant.
